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Background: The number of HIV-related hospitalizations has decreased worldwide in recent years owing to the
availability of highly active antiretroviral therapy. However, the change in HIV-related hospitalizations in Portugal has
not been studied. Using comprehensive hospital discharge data from mainland Portuguese hospitals, we examined trends
in HIV-related inpatient admissions, length of stay (LOS), Elixhauser comorbidity measures, in-hospital mortality, and mean
cost from 2000 to 2010.
Methods: The hospital administrative data from inpatient admissions and discharges at 75 public acute care hospitals in
the Portuguese National Health Service from 2000 to 2010 were included. HIV-related admissions were identified using
the International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 042.x–044.x. The effect of
Elixhauser comorbidity measures on extending the LOS was assessed by comparing admissions in HIV patients with and
without comorbidities using the Mann–Whitney U test. Multivariate logistic regression was performed to estimate the
odds of having a decreased discharge.
Results: A total of 57,027 hospital admissions were analyzed; 73% of patients were male, and the mean age was 39 years.
The median LOS was 11 days, and the in-hospital mortality was 14%. The mean cost per hospitalization was 5,148.7€. A
total of 83% of admissions were through the emergency room. During the period, inpatient HIV admissions decreased by
22%, LOS decreased by 9%, and in-hospital mortality dropped by 12%. Elixhauser comorbidities increased the median
LOS in nearly all admissions.
Conclusions: Despite small regional variations, a strong, consistent decrease was observed in the hospital admission rate,
mean cost, length of stay, and mortality rate for HIV-related admissions in Portugal during 2000–2010.
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Since the HIV epidemic emerged in Portugal in 1983,
39,347 cases have been reported, and as of 2010, 16,370
patients have developed advanced HIV infection [1].
Although the incidence of advanced HIV infection is
declining worldwide, the population of persons living
with HIV (PLWHIV) continues to rise [2]. Studies show
that the number of HIV-related hospitalizations has* Correspondence: ecassoco@gmail.com
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unless otherwise stated.decreased in recent years primarily because of the avail-
ability of highly active antiretroviral therapy (HAART)
[3-6]. This decrease has been accompanied by an increase
in the population of PLWHIV worldwide, which was esti-
mated at 34 million people (31.6–35.2 million) through
2010, a 17% increase since 2001 [7]. HIV-infected individ-
uals are surviving and experiencing longer life expectan-
cies, as well as age-associated comorbidities [8].
Accordingly, the number of hospitalizations has emerged
as an important outcome measure and contributor to
healthcare expenditures in this population.
To determine the relationship between non-AIDS co-
morbidities and the progression of HIV disease, in thetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Portugal Nomenclature of Territorial Units for Statistics
II (NUTS II) regional map. The Norte, Centro, Lisbon, Alentejo, and
Algarve regions were included in the present study.
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Index (ECI), which is a comorbidity classification system
used to describe and compare patient populations. The
ECI can adjust for confounding effects caused by the
potential chronic disease burden when a condition is as-
sociated with a particular outcome [9]. In a previous
study, we found that the ECI was associated with sub-
stantial increases in the frequency and duration of
hospitalization, and mortality [10]. The ECI evaluates 30
comorbidities including HIV; however, we applied the
ECI without including HIV as a comorbidity.
The impact on the Portuguese population of the reduc-
tion in HIV/AIDS-related morbidity and hospitalization in
the HAART era has not been thoroughly characterized,
and only one known study, which primarily examines mor-
tality, has been published [11]. An understanding of the fac-
tors affecting HIV-related hospitalizations would help
optimize resource allocation among regions and could
potentially reduce the hospitalization rate for PLWHIV.
The Portuguese health system comprises three coexist-
ing systems: the National Health Service (NHS), special
social health insurance programs for certain professions
(health subsystems), and elective private health insur-
ance. The NHS establishes the right of all citizens to
health protection; all citizens have a guaranteed univer-
sal right to health care through the NHS. The patient
pays a specific fixed cost per use for certain health care
services delivered by NHS facilities, but HIV drugs are
provided free of charge to all HIV patients [12,13].
Using comprehensive hospital discharge data from
Portuguese hospitals, we examined the trends in HIV-
related inpatient admissions, length of stay (LOS),
mean costs, ECI, and HIV in-hospital mortality from
2000 to 2010.
Methods
This cross-sectional study examined trends in HIV-
related inpatient admissions in Portugal. Hospital
administrative data were collected from public acute
care hospitals in the Portuguese NHS database main-
tained by the Central Health System Administration
(ACSS). Anonymity was maintained for all hospitals and
patients. The dataset included 10,586,118 discharges
across 75 hospitals in mainland Portugal from January
2000 to December 2010. The dataset also included the
principal diagnosis, defined as the principal condition
causing the patient’s admission to the hospital, and up to
19 additional diagnoses.
To capture all of the potential HIV hospital admis-
sions, eligible cases met one of the following criteria: (1)
principal diagnosis of HIV/AIDS as defined by the Inter-
national Classification of Diseases, Ninth Revision, Clin-
ical Modification (ICD-9-CM) with diagnosis codes of
042.x–044.x; (2) principal diagnosis of advanced HIVinfection (i.e., pneumonia or opportunistic infection as
defined by the Major Diagnostic Category 25, “Human
Immunodeficiency Virus Infection” [14-16] and a sec-
ondary diagnosis of HIV/AIDS; or (3) principal diagnosis
unrelated to HIV/AIDS and a secondary diagnosis of
HIV/AIDS. Comorbidities were defined as diagnoses
other than HIV/AIDS as defined above.
The country-wide distribution of hospitals was deter-
mined using the Nomenclature of Territorial Units for
Statistics II (NUTS II), which is a geocode standard de-
veloped by the European Union for referencing the ad-
ministrative divisions of countries for statistical
purposes. The NUTS II level identifies the region by a
two-digit or letter-digit code [17] and is only applied to
the mainland regions of Portugal, namely Norte, Centro,
Lisbon, Alentejo, and Algarve (Figure 1).
From 2000 to 2010, five administrative regulations
were issued by the Ministry of Health to assign and up-
date the costs for inpatient admissions according to
diagnosis-related groups (DRGs). Two DRGs were used
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hospitalization and the mean yearly cost for each HIV
inpatient admission were calculated using both the reg-
ulations and discharge DRGs as follows: for the year
2000, regulation 348-B/1998; for 2001–2002, regulation
189/2001; for 2003–2005, regulation 132/2003; for
2006–2008, regulation 567/2006; and for 2009–2010,
regulation 132/2009. The DRG 488–490 was used from
2000–2005, and the DRG 700–716 was used from





488 HIV with an extensive procedure in the operating room
489 HIV with a significant related clinical situation.




700 Tracheostomy for HIV.
701 Infection with HIV and an operation and ventilation
or nutritional support.
702 HIV infection with an operation room procedure and
multiple related major infections.
703 HIV infection with a block operative procedure and
related major diagnosis.
704 HIV infection with an operating room procedure with
no related major diagnosis.
705 HIV infection with multiple related major infections,
including tuberculosis.
706 HIV infection with multiple related major infections,
not including tuberculosis.
707 HIV infection with a nutritional support or ventilator.
708 HIV infection with a related major diagnosis, discharge
against medical advice.
709 HIV infection with multiple related major diagnoses
or significant diagnoses, including tuberculosis.
710 HIV infection with multiple related major diagnoses
or significant diagnoses, not including tuberculosis.
711 HIV infection with a major related diagnosis without
multiple related major or significant diagnoses,
including tuberculosis.
712 HIV infection with a major related diagnosis without
multiple related major or significant diagnoses, not
including tuberculosis.
713 HIV infection associated with a significant diagnosis,
discharge against medical advice.
714 HIV infection with significant related diagnosis.
715 HIV infection with other related diagnoses.
716 HIV infection with no other related diagnoses.
*MCD =Major Category Diagnosis.
**DRG = Diagnosis-related group.The hospitalization rate was calculated from the
2000–2010 data on HIV infection in Portugal published
by the Direcção-Geral de Saúde [18]. The mid-year
population of PLWHIV was calculated per year by
summing the new and old cases, and dividing the result
by two.
Analysis
Variations in the HIV-related hospitalization rates ac-
cording to clinical characteristics were assessed bystry of Health assigning hospitalization costs according to
Ordinances
348-B/1998 189/2001 132/2003 567/2006 132/2009
. € 2,193.50 € 11,889.72 € 13,099.08
€ 1,121.30 € 7,181.14 € 7,911.56
er € 664.80 € 3,007.10 € 33,212.97
€ 39,162.25 € 40,062.90
€ 14,467.48 € 14,800.20
€ 11,771.16 € 12,041.88
€ 10,433.90 € 10,673.86
€ 6,235.18 € 6,378.58
€ 8,737.55 € 8,938.49
€ 8,666.81 € 8,866.13
€ 8,421.56 € 8,615.24
€ 3,597.43 € 3,680.16
€ 8,322.24 € 8,513.64
€ 5,896.94 € 6,032.56
€ 5,030.96 € 5,146.67
€ 3,277.22 € 3,352.59
€ 1,847.90 € 1,890.40
€ 2,980.44 € 3,048.99
€ 1,725.63 € 1,765.32
€ 1,568.69 € 1,604.77
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amined the number of HIV-related admissions per year
according to the NUTS II region, median LOS, in-
hospital mortality, mean cost, admission type, age, and
sex. The units of analysis comprised each combination
of sex (two categories), age (four categories), NUTS II
region (five categories), year (11 categories), LOS, mor-
tality, and mean cost. The results are represented as the
frequency, median, and interquartile range, or as the
mean and 95% confidence interval (CI), as appropriate.
The impact of the ECI on the LOS was determined by
comparing admissions in patients with and without
comorbidities using the Mann–Whitney U test at a 0.05
level of significance.
Multivariate logistic regression was performed to esti-
mate the odds of having a decreased discharge status ac-
cording to all HIV-patient and independent variables,
including age (first age category served as the standard:
0 to 17 years, 18 to 45 years, 46 to 65 years, and 66 years
and older), gender (males compared with females), LOS,
and Elixhauser comorbidities (each comorbidity admis-
sion was compared with another admission without that
comorbidity), with a p-value < 0.05 indicating statistical
significance. The variables (comorbidities) included in
multivariate logistic regression analysis were selected
based on the results of a univariate analysis. Despite the
large number of variables (comorbidities), their use is
relevant given their influence on hospital outcomes, par-
ticularly on mortality, LOS, and the use of hospital re-
sources. In addition, the study population is quite large
and includes many deceased patients; therefore, many
cases exist for each predictor and independent variable.
The statistical analyses were performed using SPSS ver-
sion 21 (SPSS IBM, New York, USA).
Ethical standards
This study employed secondary anonymous data and
was performed in accordance with the ethical stan-
dards established by the 1964 Declaration of Helsinki
and its later amendments. The data were used for sci-
entific research purposes under the Medicine Faculty
of University of Porto and Central Health System
Administration agreement.
Results
From 2000 to 2010, 57,027 HIV-related hospital admis-
sions occurred in mainland Portugal. The frequency of
admissions decreased during the period, from 5,459 epi-
sodes in 2000 to 4,254 episodes in 2010. Additionally,
70% of admissions were male patients, and the mean age
increased from 35 years in 2000 to 44 years in 2010. A
total of 70% of all admissions were patients aged be-
tween 18 and 45 years. The median LOS decreased from
12 days in 2000 to 10 days at the end of the decade.During this time, 8,203 deaths were reported, and the
mortality rate decreased from 14.9% to 13.1% (Table 2).
When examined by the NUTS II region (Table 3), ad-
missions were most frequent in Lisbon and Norte, which
was expected as these are the most populous areas in
Portugal. From 2000 to 2010, the number of inpatient
admissions decreased by 35% in Lisbon, 22% in Algarve,
and 4% in Norte, but increased by 31% in Centro and
approximately 20% in Alentejo. The in-hospital mortality
rate in Norte decreased by 40% over the period, from
19.1% in 2000 to 11% in 2010, while in Centro, the mor-
tality decreased by only 24%, dropping from 10% in
2000 to 7.7% in 2010. In Lisbon, Alentejo, and Algarve,
the mortality rates increased by 3%, 34%, and 52%, from
14.5%, 17%, and 8.3% in 2000 to 15%, 23%, and 12% in
2010, respectively. The most deaths in the Norte region
(19%) occurred in 2000, for Centro (15%) in 2006, for
Lisbon (16%) in 2001, for Alentejo (24%) in 2002, and
for Algarve (15%) in 2003.
The median LOS was 11 days (interquartile range 5–
22 days). Between 2000 and 2010, the median LOS
across mainland Portugal decreased by 25% (from 12 to
9 days) in the Norte region, 18% (from 11 to 9 days) in
the Centro and Alentejo regions, and 8% (from 12 to
11 days) in the Lisbon region, while the median LOS in
the Algarve region increased by 8% (from 11 to 13 days).
The median LOS was significantly higher in men
(12 days; interquartile range 5–23 days) than in women
(10 days; interquartile range 2–23 days). This difference
was statistically significant (p < 0.001) using the Mann–
Whitney U test (data not shown).
Hospitalization occurred primarily in two ways:
through the emergency room or through an ambulatory
consultation. When the data were examined according
to the site of admission, we found that 83% of hospitali-
zations originated from the emergency room. Planned
admissions fluctuated substantially during the study
period. In 2000, there were 757 planned admissions,
which increased to 1,238 admissions in 2004, to 963 ad-
missions in 2005, and to 686 admissions in 2010. The
number of admissions from the emergency room in-
creased slightly over the period, from 4,702 admissions
in 2000 to 3,573 by 2010 (Additional file 1: Table S1).
The mean cost per HIV admission decreased during
the study period and substantially decreased in the
Norte, Centro, and Lisbon regions. The mean cost in the
Norte region was 5,499€ (95% CI 5,555€–5,444€) over
the entire study period, with 2003 and 2004 as the most
expensive years (7,137€ and 7,181€; 95% CI 7,006€–
7,269€ and 7,058€–7,305€, respectively). In Centro, the
overall mean cost was 4,739€ (95% CI 4,822€–4,657€),
with 2003, 2004, and 2005 as the most expensive years
(6,393€, 6,593€, and 6,474€; 95% CI 6,183€–6,603€,
6,372€–6,814€ and 6,243€–6,704€, respectively). In
Table 2 Population, hospitalization, and mortality trends in HIV-related inpatient admissions in Portugal
Linear regression
Variables Total 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 slop 95% IC
Mid-year populations of persons living with HIV* 4,466 4,993 5,524 6,010 6,437 6,854 7,213 7,521 7,819 8,052 8,289 382.127 [341.991:422.264]
HIV/AIDS hospitalization frequency 57,027 5,459 5,550 5,654 5,628 5,468 5,491 5,214 5,089 4,894 4,326 4,254 −132.118 [−186.756: −77.480]
Hospitalization rate# 1.2 1.1 1.0 0.9 0.8 0.8 0.7 0.7 0.6 0.5 0.5 −0.069 [−0.078: −0.060]
Gender (% male) 73 76 76 76 74 74 73 74 72 70 70 70 −0.691 [−0.854:−0.528]
Age (mean) 39 35 37 38 38 39 41 41 42 42 43 44 0.827 [0.709:0.946]
Median LOS (days) 11 12 12 12 11 12 12 11 11 11 10 10 −0.200 [−0.296:−0.104]
In-hospital mortality (%) 14.4 14.9 15.5 15.4 15.1 14.9 14.8 13.8 13.4 13.1 13.4 13.1 −0.262 [−0.349:−0.175]
Average cost (€) 5,148.7 997.7 4,818.1 6,062.0 6,625.6 6,689.7 6,640.8 5.676.4 4,480.0 4,670.4 4,594.1 4,664.0 72.329 [−293.079:437.737]
Total cost in M (€) 293,614 5,446 26,740 34,274 37,288 36,579 36,464 29,596 22,798 22,856 19,874 19,840 −233.736 [−2437.823:1970.350]
*Data published in “Infecção VIH/SIDA: A Situação em Portugal a 31 de Dezembro de 2010,” by the Departamento de Doenças Infecciosas.
#Calculated by dividing the mid-year population of persons living with HIV by the number of hospitalization episodes due to HIV per year.
















Table 3 Median HIV inpatient admissions in Portugal by NUTS II region and year
NUTS II / Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total % Change (2000–2010)
Norte, N 1,191 1,274 1,356 1,298 1,327 1,473 1,384 1,374 1,294 1,208 1,139 14,318 −4.4
Median LOS 12 11 11 12 13 12 10 11 10 9 9 10.9 −25
% Death 19.1 17.7 17.6 16.4 15.4 15.3 11.7 13.8 12.8 13.5 11.4 15.0 −40.1
Centro, N 415 449 563 552 528 565 539 535 604 536 546 5,832 31.6
Median LOS 11 11 11 11 11 10 10 11 10 10 9 10.4 −18.2
% Death 10.1 9.4 12.4 8.9 10.8 11.3 14.8 11.2 7.3 7.5 7.7 10.1 −24.0
Lisbon, N 3,511 3,412 3,319 3,366 3,237 3,020 2,908 2,712 2,609 2,226 2,272 32,592 −35.3
Median LOS 12 12 12 11 12 12 12 11 12 11 11 11.6 −8.3
% Death 14.5 16.1 15.0 15.7 15.3 15.2 14.5 13.8 14.2 14.4 15.0 14.9 3.4
Alentejo, N 76 100 103 132 111 143 137 129 114 98 91 1,234 19.7
Median LOS 11 10 13 11 12 10 9 9 11 10 9 10.4 −18.2
% Death 17.1 12.0 24.3 15.2 22.5 16.8 17.5 17.1 19.3 19.4 23.1 18.4 34.9
Algarve, N 266 315 313 280 265 290 246 339 273 258 206 3,051 −22.6
Median LOS 12 12 11 10 11 12 12 11 11 14 13 11.7 8.3
% Death 8.3 10.2 12.1 14.6 12.8 14.1 12.2 11.2 14.3 14.3 12.6 12.4 52.6
Total, N 5,459 5,550 5,654 5,628 5,468 5,491 5,214 5,089 4,894 4,326 4,254 57,027 −22.1
Median LOS 11.5 11.2 11.6 11.0 11.8 11.2 8.0 10.6 10.8 10.8 10.2 11.0 −8.9
% Death 14.9 15.5 15.4 15.1 14.9 14.8 13.8 13.4 13.1 13.4 13.1 14.4 −11.7
NUTS II = Nomenclature of Territorial Units for Statistics II; LOS = length of stay.
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most expensive years were 2004 to 2006, with a mean
admission cost of over 6,000€ during this period. In
Alentejo, the mean admission cost was 5,210€ (5,411€–
5,009€). The most expensive years were 2002 to 2005,
averaging over 6,000€ each year. In Algarve, the mean
admission cost was 4,999€ (95% CI 5,123€–4,875€).Table 4 Mean costs for HIV inpatients in Portugal by year and
Year Norte Centro Lisbon
Mean(€) (95% IC) Mean(€) (95% IC) Mean(€)
2000 1051.0 (1036.8–1065.2) 953.7 (925.2–982.2) 1024.0
2001 5099.2 (4928.6–5269.9) 4597.4 (4327.0–4867.8) 4808.6
2002 6480.8 (6376.0–6585.6) 5654.6 (5471.4–5837.7) 6209.4
2003 7137.9 (7006.4–7269.4) 6393.4 (6183.0–6603.9) 6798.8
2004 7181.7 (7058.0–7305.3) 6593.4 (6372.1–6814.7) 6855.2
2005 6894.7 (6772.8–7016.6) 6474.0 (6243.6–6704.4) 6746.2
2006 5924.8 (5777.3–6072.3) 5286.5 (5044.9–5528.1) 6056.5
2007 5110.8 (4936.9–5284.8) 3793.2 (3579.2–4007.2) 4951.4
2008 5301.3 (5103.1–5499.6) 3930.2 (3717.3–4143.1) 5053.6
2009 4907.5 (4705.1–5109.9) 4244.9 (3956.7–4533.1) 4995.3
2010 4733.4 (4553.7–4913.1) 3919.6 (3640.1–4199.1) 4917.4
All years 5499.9 (5555.0–5444.9) 4739.8 (4822.1–4657.6) 5293.2
The cost per hospitalization was estimated using the following administrative regul
Portaria 189/2001, Portaria 132/2003, Portaria 567/2006, and Portaria 132/2009. The
DRGs 700–716 were used from 2003 to 2010. A total of 25 Major Diagnostic Catego
to 2010.
NUTS II = Nomenclature of Territorial Units for Statistics; 95% CI = 95% confidence intThe mean HIV admission cost in mainland Portugal
was lowest in 2001 (Table 4). The mean daily cost was
253€ and increased slightly over the decade from 248€
to 260€ (4% increase), while the estimated cost per year
decreased considerably from 19 to 15 million euros
over the decade (12% decrease). Overall, an estimated
208 million euros were spent on patients with HIV andNUTS II
Alentejo Algarve
(95% IC) Mean(€) (95% IC) Mean(€) (95% IC)
(1014.2–1033.8) 982.7 (926.0–1039.4) 977.3 (939.4–1015.2)
(4699.8–4917.5) 4961.2 (4324.1–5598.3) 4624.3 (4281.1–4967.4)
(6126.9–6291.9) 6356.6 (5986.9–6726.4) 5608.6 (5353.4–5863.8)
(6710.4–6887.3) 6370.8 (5911.5–6830.2) 6427.0 (6140.4–6713.7)
(6766.0–6944.4) 6418.4 (5944.1–6892.7) 6399.7 (6099.1–6700.3)
(6651.4–6840.9) 6459.4 (6061.0–6857.8) 6629.9 (6339.5–6920.4)
(5946.7–6166.3) 5601.4 (5096.8–6105.9) 5512.6 (5181.2–5844.1)
(4818.9–5083.8) 4335.4 (3541.7–5129.0) 4209.3 (3921.6–4497.0)
(4903.7–5203.5) 4403.5 (3849.7–4957.3) 4663.4 (4019.3–5307.5)
(4814.3–5176.3) 3898.9 (3375.5–4422.2) 4923.9 (4450.5–5397.3)
(4759.6–5075.1) 5169.6 (3923.7–6415.5) 4579.8 (4169.3–4990.4)
(5332.5–5.254.0) 5210.9 (5411.8–5009.9) 4999.5 (5123.3–4875.7)
ations (named “Portaria”) from the Ministry of Health: Portaria 348-B/1998,
diagnosis-related groups (DRGs) 488–490 were used from 2000 to 2003, and
ries (MDCs) were used from 2000 to 2003, and 24 MDCs were used from 2003
erval.
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the most expensive (Additional file 1: Table S2 and
Table S3).
Based on the ECI, drug abuse was identified in 30% of
patients, liver disease in 24%, and fluid and electrolyte
disorders in 9%. Nearly every comorbidity significantly
increased the LOS. The comorbidities associated with
the greatest increase in the median LOS were paralysis
(12 days), valvular heart disease (8 days), and hemorrhage
(8 days; Table 5).When the Elixhauser comorbidities wereTable 5 Distribution of Elixhauser comorbidity measures in H
Comorbidity Frequency % M
%
Paralysis 708 1 76
Blood loss and anemia 1,943 3 71
Valvular heart disease 620 1 74
Deficiency anemia 1,889 3 65
Depression 1,597 3 77
Weight loss 3,753 7 73
Pulmonary circulation disorders 414 1 65
Peptic ulcer disease excluding bleeding 205 0 45
Hypothyroidism 148 0 37
Other neurological disorders 3,329 6 78
Metastatic cancer 537 1 81
Rheumatoid arthritis/collagen vascular diseases 490 1 68
Diabetes, complicated 397 1 65
Peripheral vascular disorders 230 0 87
Fluid and electrolyte disorders 5,189 9 85
Solid tumor without metastasis 2,905 5 82
Congestive heart failure 1,029 2 73
Cardiac arrhythmias 877 2 71
Psychoses 616 1 71
Liver disease 13,905 24 80
Alcohol abuse 4,578 8 73
Coagulopathy 3,187 6 73
Chronic pulmonary disease 2,458 4 66
Lymphoma 1,471 3 55
Hypertension, uncomplicated 2,191 4 67
Diabetes, uncomplicated 1,709 3 70
Hypertension, complicated 518 1 72
Renal failure 1,929 3 66
Drug abuse 16,978 30 81
Obesity 225 0 76
*LOS with a specific comorbidity is defined as the days above the median LOS in p
comorbidity was 11 days for all hospitalization episodes.
#Statistical significance was determined by the Mann–Whitney U test with significan
¥Number of people in each gender per 1,000 inpatients diagnosed with a specific c
LOS = length of hospital stay.examined by gender, because of the predominantly male
population, most comorbidities occurred in men (73%).
When the number of comorbidity cases was examined by
sex per thousand episodes (men 41.834 and women
15.210), twice as many women as men were diagnosed
with chronic pulmonary disease, uncomplicated hyperten-
sion, and depression.
We also examined the number of etiologies causing
the hospitalizations; the cause of hospitalization was cat-
egorized as related or not directly related to HIV. HIV-IV inpatients by gender and length of stay
ale (n = 41,834) Female(n = 15,210) LOS/SCm*
‰¥ % ‰¥ (Median) p-value#
13 24 11 12 <0.001
33 29 37 8 <0.001
11 26 11 8 <0.001
30 35 43 6 <0.001
27 23 22 6 <0.001
66 27 66 5 <0.001
6 36 10 5 <0.001
2 55 8 5 <0.001
1 64 6 5 <0.001
60 22 46 4 <0.001
10 19 7 4 <0.001
9 32 11 4 <0.001
6 35 9 4 0.008
5 14 2 4 <0.001
93 15 46 3 <0.001
57 18 34 3 <0.001
18 27 19 3 <0.001
15 29 17 3 <0.001
11 29 12 3 <0.001
264 21 188 2 <0.001
91 27 92 2 <0.001
58 27 59 2 <0.001
39 34 55 2 <0.001
21 45 48 2 <0.001
35 33 47 1 0.001
29 30 34 1 0.062
9 28 9 1 0.001
31 34 43 0 0.425
329 19 211 0 0.037
4 24 3 −1 0.047
atients without this comorbidity. The median LOS without each specific
ce at p < 0.05.
omorbidity.
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study period from 82% to 75%, while hospitalizations
unrelated to HIV increased from 18% to 25%. Deaths
directly caused by HIV decreased from 16% to 14%, while
deaths from causes unrelated to HIV increased from 9%
to 12% over the decade (Additional file 1: Table S4).
In the multivariate regression analysis (adjusted and
unadjusted) of HIV admissions between 2000 and
2010, we examined the variables influencing the riskTable 6 Multivariate regression analyses of death odds for HI
Independent variables N (% dead) OR una
Age groups - years of age
1 - 0 to 17 1,057 (2.9) 1
2 - 18 to 45 40,635 (13.3) 5.068
3 - 46 to 65 12,803 (17.1) 6.837
4 - 66 and older 2,544 (22.9) 9.840
Sex
Female 15,210 (11) 1
Male 41,834 (15.6) 1.500
LOS median (alive/deceased) 11.0 / 12.0 1.005
Elixhauser comorbidity measures
No comorbidity* 16,850 (9.7) 1
Metastatic cancer 537 (41.5) 4.319
Weight loss 3,753 (30.8) 2.917
Fluid and electrolyte disorders 5,189 (29.9) 2.897
Lymphoma 1,471 (27.5) 2.319
Pulmonary circulation disorders 414 (22.9) 1.782
Cardiac arrhythmias 877 (31.1) 2.749
Solid tumor without metastasis 2,905 (24.1) 1.973
Coagulopathy 3,187 (23.8) 1.953
Blood loss and anemia 1,943 (22.6) 1.780
Peripheral vascular disorders 230 (23.9) 1.877
Congestive heart failure 1,029 (22.6) 1.765
Other neurological disorders 3,329 (20.2) 1.551
Paralysis 708 (21.6) 1.654
Renal failure 1,929 (18.9) 1.403
Peptic ulcer disease excluding bleeding 205 (20.5) 1.537
Alcohol abuse 4,578 (18.1) 1.348
Liver disease 13,905 (15.2) 1.087
Hypertension, uncomplicated 2,191 (12.7) 0.861
Chronic pulmonary disease 2,458 (11) 0.726
Depression 1,597 (9.8) 0.642
Nutrient-deficiency anemia 1,889 (10.7) 0.706
Obesity 225 (7.1) 0.455
*Patients with each comorbidity were compared with patients without that comorb
model and were not included in the analysis, namely rheumatoid arthritis/collagen v
uncomplicated and complicated), complicated hypertension, and hypothyroidism.
LOS = length of hospital stay; OR = odds ratio; 95% CI = 95% confidence interval.of death. The risk of death increased primarily with
age. Men had a 1.5 odds ratio for death compared
with women. The LOS did not affect the odds ratio
for death. Comorbidities, such as metastatic cancer,
weight loss, fluid and electrolyte disorders, lymphoma,
pulmonary circulation disorders, and cardiac arrhyth-
mias, increased the death odds ratio more than two
times compared with admissions without those co-
morbidities (Table 6).V inpatients by age, sex, LOS, and comorbidities
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The decline in HIV-related hospital admissions during the
final 4 years of the study period (2007–2010) was in
opposition to the trend over the first 7 years (2000–2006)
in which the number of episodes increased. The HIV inci-
dence appears to have decreased by nearly 50% in one
decade. These data indicate success in controlling HIV in
Portugal. This success is good considering that the world-
wide HIV incidence is also decreasing (nearly 20% over
the study period) [19].
Because HIV is a chronic disease, affected patients
experience numerous acute exacerbations. In the present
study, 80% of patients were hospitalized because of an
acute illness, which highlights the challenge of clinical
management and control of HIV. These acute episodes
are more common in men because they form the major-
ity of HIV patients in Portugal, as in the rest of Europe
[20]. Worldwide, half of HIV patients are men, though
in certain regions, such as Africa and the Caribbean,
women predominate [7]. Over the study decade, the me-
dian age increased by 10 years, confirming that many
PLWHIV are surviving longer [2,21,22].
The overall inpatient LOS decreased during the dec-
ade, though the rate increased during the most recent
years. This trend may reflect improved access to out-
patient care and better adherence to HAART [23].
Fleishman and Hellinger [3] studied trends in HIV-
related inpatient admissions in seven states in the USA
(1996–2000) and found a comparatively shorter LOS
(median 6 days) that was half the LOS observed in this
study. Characteristics unique to the Portuguese NHS
may explain this difference. One reason could be that to
discharge a patient in Portugal, several guarantees
should be met, such as adequate family support, and
continued care at home or at a center providing social
assistance; these requirements likely increase the LOS.
When the LOS for HIV-related admissions was com-
pared with the LOS for all other admissions, HIV-
related admissions showed a greater median LOS than
all other admissions. While the LOS for HIV-related ad-
missions decreased compared with all other admissions,
this trend was not statistically significant.
Trends in mortality varied across regions, with Norte
and Centro differing significantly from Lisbon, Alentejo,
and Algarve. Overall, the in-hospital mortality rate de-
creased by 12%. In the Norte and Centro regions, the
decrease between 2000 and 2010 was approximately 40%
and 24%, respectively. In Lisbon and Algarve, the mor-
tality rate increased steadily during the period; this result
contrasts with the overall decreased mortality over the
same period. Many mechanisms may underlie this dis-
crepancy; the treatment methods and patient follow-up
protocols are similar across the country, while the abso-
lute frequency of admissions varies by region. TheAlentejo and Algarve regions had fewer episodes; there-
fore, one death may have greater weight than a death in
the northern regions where there are more HIV
inpatient admissions. Thus, the discrepancy may be due
to significant differences in the population itself, rather
than in the quality of care. Our results show a substan-
tial decrease in the mortality rate. This decrease might
be due to HAART or improved monitoring of HIV
patients through outpatient hospital services and health
centers in the area of residence. These data confirm pre-
viously published data showing that the HIV-related
mortality in Europe has decreased since 1996 [24,25].
The mean estimated cost increased from 2000 to 2001,
stabilized with little fluctuation from 2001 to 2005, and
decreased steadily from 2006 to 2010. There were no
regional differences, and the admission complexity did
not appear to vary over the period. Even considering that
the prices are set by the Ministry of Health, the mean
cost showed a clear decreasing trend, which may be due
to the decreased number of cases or improved clinical
management over the decade. However, the mean daily
cost per admission increased over the same period.
These results contradict the lower daily costs reported
by Perelman et al. [26].
Regression analyses for the risk of HIV inpatient mortal-
ity were performed for age, sex, LOS, and ECI. The risk of
death increased over four-fold with age, but the difference
was not significant in patients older than 18 years, as indi-
cated by the overlap in the 95% CIs. Men had a greater risk
of death than women did, and the LOS did not influence
the risk of mortality. Most comorbidities increased the risk
of death. Metastatic cancer increased the risk three-fold.
Several comorbidities did not influence the risk of death,
including complicated or uncomplicated hypertension,
chronic pulmonary disease, obesity, nutrient-deficiency
anemia, psychosis, and depression.
This study used comprehensive discharge data com-
piled in mainland Portugal. Thus, the findings are more
generalizable than results based on data from a single
hospital. However, this study has limitations, due pri-
marily to the nature of the data [27]. First, we cannot
identify the number of unique patients, the number of
times that one patient was hospitalized at a single facil-
ity, or the number of years in care. Important clinical
information, mainly complementary exams (CD4 cell
count, viral load) and the therapy used, was not avail-
able. To track the long-term outcomes and quality of
care, an electronic database or electronic health record
system specially designed to capture these important
components of HIV-related care is necessary.
Conclusions
We found a strong, consistent decrease in the hospital
admission rate, cost, LOS, and mortality rate during
Catumbela et al. BMC Health Services Research  (2015) 15:144 Page 10 of 102000–2010. Although the rate of hospitalization directly
related to HIV has decreased over time, HIV remains a
major cause of hospitalization. Further scrutiny is neces-
sary to explain this trend during the HAART era. The
National Health Service appears to have persistently im-
proved outcomes over the previous decade. However,
there is an increased need for studies evaluating the con-
straints on hospital care of HIV/AIDS patients to deter-
mine the measures needed to improve the prevention
and management of comorbidities in PLWHIV.
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